- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cytogen completes CytoRad acquisition
Monoclonal antibody developer Cytogen put the finishing touches on its acquisition of sistercompany CytoRad last month. CytoRad will now be a wholly ownedsubsidiary of Cytogen, the Princeton, NJ, company said. CytoRad was initially formed as a separate
Monoclonal antibody developer Cytogen put the finishing touches on its acquisition of sistercompany CytoRad last month. CytoRad will now be a wholly ownedsubsidiary of Cytogen, the Princeton, NJ, company said.
CytoRad was initially formed as a separate company to pay forR&D at Cytogen, but the two firms began feuding last yearand CytoRad cut off funding (SCAN 6/29/94 and 4/20/94). The disputecontributed to a shortfall of millions of dollars in Cytogen'srevenues last year (SCAN 3/1/95).
The acquisition will resolve the differences between the companiesand will assure Cytogen of a stable source of R&D funds. Cytogenbought CytoRad by trading each share of CytoRad stock for 1.5shares of Cytogen common stock, a warrant expiring in 1997 toacquire one share of Cytogen common stock for $8 a share, anda contingent value right (CVR) to receive additional shares ofCytogen stock if certain conditions are met.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
